Læknablaðið - 15.06.2000, Blaðsíða 21

FRÆÐIGREINAR / BARNAGEÐLÆKNINGAR
50. Biederman J, Thisted RA, Greenhill LL, Ryan ND. Estima-
tion of the association between desipramine and the risk for
sudden death in 5- to 14-year-old children. J Clin Psychiatry
1995; 56:87-93.
51. Jankovic J. Deprenyl in attention defícit associated with
Tourette's syndrome. Arch Neurol 1993; 50: 286-8.
52. Zametkin A, Rapoport JL, Murphy DL, Linnoila M, Karoum
F, Potter WZ, et al. Treatment of hyperactive children with
monoamine oxidase inhibitors. II. Plasma and urinary mono-
amine findings after treatment. Arch Gen Psychiatry 1985; 42:
969-73.
53. Hunt RD, Minderaa RB, Cohen DJ. Clonidine benefits
children with attention deficit disorder and hyperactivity: re-
port of a double-blind placebo-crossover therapeutic trial. J
Am Acad Child Psychiatry 1985; 24:617-29.
54. Silver LB. Alternative (nonstimulant) medications in the
treatment of attention-deficit/hyperactivity disorder in child-
ren. Pediatr Clin North Am 1999; 46: 965-75.
55. Connor DF, Fletcher KE, Swanson JM. A meta-analysis of
clonidine for symptoms of attention-deficit hyperactivity dis-
order. J Am Acad Child Adolesc Psychiatry 1999; 38:1551-9.
56. Olvera RL, Pliszka SR, Luh J. Tatum R. An open trial of
venlafaxine in the treatment of attention-deficit/hyperactivity
disorder in children and adolescents J Am Acad Child
Adolesc Psychiatry 1996;6: 241-50.
57. Pleak RR, Gormly LJ. Effects of venlafaxine treatment for
adhd in a child [letter]. Am J Psychiatry 1995;152:1099.
58. Spencer T, Biederman J, Wilens T. Pharmacotherapy of atten-
tion deficit hyperactivity disorder. Child Adolesc Psychiatr
Clin N Am 2000; 9: 77-97.
59. Wilens TE, Spencer T, Biederman J, Wozniak J, Connor D.
Combined pharmacotherapy: an emerging trend in pediatric
psychopharmacology. J Am Acad Child Adolesc Psychiatry
1995;34:110-2.
60. Barkley RA. Developmental course, adult outcome, and
clinic-referred adhd adults. In: Barkley RA, ed. Attention
Defícit/Hyperactivity disorder. A handbook for diagnosis and
treatment. 2nd ed. New York: Guilford; 1998:186-224.
61. Anastopoulos AD, Shelton TL, DuPaul GJ, Guevremont DC.
Parent training for attention-deficit hyperactivity disorder: its
impact on parent functioning. J Abnorm Child Psychol 1993;
21:581-96.
62. Pelham Jr WE, Wheeler T, Chronis A. Empirically supported
psychosocial treatments for attention deficit hyperactivity
disorder. J Clin Child Psychol 1998; 27:190-205.
63. Bird HR, Gould MS, Staghezza BM. Patterns of diagnostic
comorbidity in a community sample of children aged 9
through 16 years. J Am Acad Child Adolesc Psychiatry 1993;
32:361-8.
64. Biederman J, Newcorn J, Sprich S. Comorbidity of attention
deficit hyperactivity disorder with conduct, depressive, an-
xiety, and other disorders. Am J Psychiatry 1991; 148:564-77.
65. Munir K, Biederman J, Knee D. Psychiatric comorbidity in
patients with attention deficit disorder: a controlled study. J
Am Acad Child Adolesc Psychiatry 1987; 26:844-8.
66. Barkley RA, DuPaul GJ, McMurray MB. Comprehensive
evaluation of attention deficit disorder with and without
hyperactivity as defined by research criteria. J Consult Clin
Psychol 1990; 58:775-89.
67. Barkley RA, Biederman J. Toward a broader definition of the
age-of-onset criterion for attention-deficit hyperactivity dis-
order. J Am Acad Child Adolesc Psychiatry 1997; 36:1204-10.
68. Silver LB. The relationship between leaming disabilities,
hyperactivity, distractibility, and behavioral problems: a
clinical analysis. J Am Acad Child Psychiatry 1981; 20: 385-97.
69. Halperin JM, Gittelman R, Klein DF, Rudel RG. Reading-
disabled hyperactive children: a distinct subgroup of attention
deficit disorder with hyperactivity? J Abnorm Child Psychol
1984; 12:1-14.
70. Barkley RA, Fischer M, Edelbrock CS, Smallish L. The
adolescent outcome of hyperactive children diagnosed by
research criteria: I. An 8-year prospective follow-up study. J
Am Acad Child Adolesc Psychiatry 1990; 29: 546-57.
71. Hart EL, Lahey BB, Loeber R, Applegate B, Frick PJ. De-
velopmental change in attention-deficit hyperactivity disorder
in boys: a four-year longitudinal study. J Abnorm Child
Psychol 1995; 23: 729-49.
72. Wilens TE, Spencer TJ, Biederman J. Pharmacotherapy Of
Adult ADHD. In: Barkley RA, ed. Attention Deficit/Hyper-
activity disorder. A handbook for diagnosis and treatment.
2nd ed. New York: Guilford 1998:552-63.
73. Cantwell DP. Attention deficit disorder: a review of the past 10
years. J Am Acad Child Adolesc Psychiatry 1996; 35: 978-87.
74. Biederman J, Wilens T, Mick E, Faraone SV, Weber W, Curtis
S, et al. Is ADHD a risk factor for psychoactive substance use
disorders? Findings from a four-year prospective follow-up
study. J Am Acad Child Adolesc Psychiatry 1997; 36: 21-9.
75. Gillberg C, Melander H, von Knorring AL, Janols LO, Thern-
lund G, Hagglof B, et al. Long-term stimulant treatment of
children with attention-deficit hyperactivity disorder symp-
toms. A randomized, double-blind, placebo-controlled trial.
Arch Gen Psychiatry 1997; 54:857-64.
76. The MTA cooperative group. A 14-month randomized clinical
trial of treatment strategies for attention-deficit/hyperactivity
disorder. Multimodal treatment study of children with adhd.
Arch Gen Psychiatry 1999; 56:1097-9.
Læknablaðið 2000/86 419